375 related articles for article (PubMed ID: 23038766)
61. Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease.
Ishihara H; Yamashita S; Liu YY; Hattori N; El-Omar O; Ikeda T; Fukuda H; Yoshida K; Takagi T; Taneda S; Kondo T; Nagashima Y; Tanabe K; Ushijima T
Cancer Sci; 2020 Nov; 111(11):4276-4287. PubMed ID: 32860304
[TBL] [Abstract][Full Text] [Related]
62. MicroRNA expression profiling of Xp11 renal cell carcinoma.
Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
[TBL] [Abstract][Full Text] [Related]
63. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
64. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
65. Microphthalmia family of transcription factors associated renal cell carcinoma.
Xie L; Zhang Y; Wu CL
Asian J Urol; 2019 Oct; 6(4):312-320. PubMed ID: 31768316
[TBL] [Abstract][Full Text] [Related]
66. Sclerosing TSC1 mutated renal cell carcinoma: An unusual pattern mimicking MITF family translocation renal cell carcinoma.
Williamson SR; Cardili L; Whiteley LJ; Sanchez J; Kis O
Genes Chromosomes Cancer; 2020 Oct; 59(10):591-594. PubMed ID: 32418252
[TBL] [Abstract][Full Text] [Related]
67. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.
Chang IW; Huang HY; Sung MT
Am J Surg Pathol; 2009 Dec; 33(12):1894-901. PubMed ID: 19809274
[TBL] [Abstract][Full Text] [Related]
68. Chromophobe renal cell carcinoma: current and controversial issues.
Moch H; Ohashi R
Pathology; 2021 Jan; 53(1):101-108. PubMed ID: 33183792
[TBL] [Abstract][Full Text] [Related]
69. [Heredity in renal and prostatic neoplasia].
Prayer Galetti T; D'Arrigo L; De Zorzi L; Patarnello T
Arch Ital Urol Androl; 1997 Sep; 69(4):241-6. PubMed ID: 9417296
[TBL] [Abstract][Full Text] [Related]
70. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester M; Dolnik A; Kornak U; Pfitzner B; Hummel M; Treue D; Hartmann A; Agaimy A; Weyerer V; Lekaj A; Brakemeier S; Peters R; Öllinger R; Märdian S; Bullinger L; Striefler JK; Flörcken A
J Pathol Clin Res; 2021 Jan; 7(1):3-9. PubMed ID: 33180365
[TBL] [Abstract][Full Text] [Related]
71. MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics.
Magers MJ; Udager AM; Mehra R
Arch Pathol Lab Med; 2015 Oct; 139(10):1224-33. PubMed ID: 26414466
[TBL] [Abstract][Full Text] [Related]
72. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
73. [Hereditary kidney cancers: The pathologist's view in 2020].
Verkarre V; Morini A; Denize T; Ferlicot S; Richard S
Ann Pathol; 2020 Apr; 40(2):148-167. PubMed ID: 32197858
[TBL] [Abstract][Full Text] [Related]
74. Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.
Kuroda N; Katto K; Tanaka Y; Yamaguchi T; Inoue K; Ohara M; Mizuno K; Hes O; Michal M; Lee GH
Med Mol Morphol; 2010 Jun; 43(2):86-90. PubMed ID: 20683695
[TBL] [Abstract][Full Text] [Related]
75. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
76. Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms.
Gatalica Z; Lilleberg SL; Vranic S; Eyzaguirre E; Orihuela E; Velagaleti G
Hum Pathol; 2009 Dec; 40(12):1813-9. PubMed ID: 19733897
[TBL] [Abstract][Full Text] [Related]
77. Origin of renal cell carcinomas.
Valladares Ayerbes M; Aparicio Gallego G; Díaz Prado S; Jiménez Fonseca P; García Campelo R; Antón Aparicio LM
Clin Transl Oncol; 2008 Nov; 10(11):697-712. PubMed ID: 19015066
[TBL] [Abstract][Full Text] [Related]
78. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
Motzer RJ; Bacik J; Mariani T; Russo P; Mazumdar M; Reuter V
J Clin Oncol; 2002 May; 20(9):2376-81. PubMed ID: 11981011
[TBL] [Abstract][Full Text] [Related]
79. The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt.
Nagi FM; Omar AA; Mostafa MG; Mohammed EA; Abd-Elwahed Hussein MR
Ultrastruct Pathol; 2011 Apr; 35(2):79-86. PubMed ID: 21299348
[TBL] [Abstract][Full Text] [Related]
80. Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.
Klomp JA; Petillo D; Niemi NM; Dykema KJ; Chen J; Yang XJ; Sääf A; Zickert P; Aly M; Bergerheim U; Nordenskjöld M; Gad S; Giraud S; Denoux Y; Yonneau L; Méjean A; Vasiliu V; Richard S; MacKeigan JP; Teh BT; Furge KA
BMC Med Genomics; 2010 Dec; 3():59. PubMed ID: 21162720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
